Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Pancreatic Neoplasms 1Melanoma 1Glioblastoma 1

Interventions

Cyclophosphamide 517Bevacizumab 488Carboplatin 424pembrolizumab 388Paclitaxel 385Gemcitabine 372Cisplatin 366Docetaxel 323Rituximab 316Radiotherapy 296Nivolumab 247Doxorubicin 243Dexamethasone 240Fluorouracil 225Capecitabine 214Oxaliplatin 211Erlotinib Hydrochloride 206fludarabine phosphate 201Etoposide 188Cetuximab 186Lenalidomide 177Pemetrexed 176Bortezomib 174Trastuzumab 173Filgrastim 171fludarabine 166Prednisone 166Leucovorin 166Cytarabine 166Irinotecan 161

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Has results × Disulfiram × Clear all
NCT03363659 2024-10-03

Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme

Wake Forest University Health Sciences

Phase 2 Terminated
15 enrolled 9 charts
CNS

Glioblastoma

NCT02101008 2023-12-13

Disulfiram and Chelated Zinc for the Rx of Disseminated Mets Mel That Has Failed First Line Therapy

University of Utah

Phase 2 Completed
12 enrolled 6 charts
Dermatologic

Melanoma

NCT03714555 2023-10-18

Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine

HonorHealth Research Institute

Phase 2 Terminated
1 enrolled 7 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡